<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02924909</url>
  </required_header>
  <id_info>
    <org_study_id>54633416.3.0000.5274</org_study_id>
    <nct_id>NCT02924909</nct_id>
  </id_info>
  <brief_title>Phase II Trial of Neoadjuvant Treatment and Minimal Invasive Surgery for Esophageal and GEJ Cancer</brief_title>
  <acronym>QUIMERA</acronym>
  <official_title>Phase II Trial of Induction Chemotherapy Followed by Chemoradiotherapy With Paclitaxel and Carboplatin Before Minimal Invasive Surgery in Patients With Localized Esophageal and Gastro-esophageal Junction Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Nacional de Cancer, Brazil</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Nacional de Cancer, Brazil</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase II trial of induction chemotherapy with carboplatin AUC 6 plus paclitaxel 175 mg/m2 in
      a 21 day cycle for two cycles followed by radiotherapy 4500 cGy in 25 fractions plus
      carboplatin AUC=2 paclitaxel 50 mg/m2 in a week regimen followed by minimally invasive
      surgery after 6 to 10 weeks. A PET scan will be performed at the time of randomization and 14
      days after de first cycle to determine the relation between metabolic response and survival.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase II trial of induction chemotherapy with carboplatin AUC 6 plus paclitaxel 175 mg/m2 in
      a 21 day cycle for two cycles followed by radiotherapy 4500 cGy in 25 fractions plus
      carboplatin AUC=2 paclitaxel 50 mg/m2 in a week regimen followed by minimally invasive
      surgery after 6 to 10 weeks. A PET scan will be performed at the time of randomization and 14
      days after de first cycle to determine the relation between metabolic response and survival.
      The primary endpoint is to the evaluate the number of complete pathologic response. The
      secondary endpoints are evaluation of toxicity, radiologic response, metabolic response,
      results of the minimally invasive surgery (blood lost, number of conversion to open surgery,
      type of resection, R0, 1 or 2, post-op complications, time of hospitalization, 30 day post-op
      mortality), evaluate the viability of treatment protocol (number of patient that complete the
      phases), evaluate quality of life during the treatment and after the surgery. Inclusion
      criterias are: Histologically proven adenocarcinoma or squamous cell carcinoma of the middle
      and lower third of the esophagus (included tumors located in the gastro-esophageal junction
      Siewert I and II), age between 18 and 75 years, Performance Status 0 or 1, neutrophils count
      &gt; 1500/mm3, platelets count &gt; 100.000/mm3, hemoglobin count &gt; 9 g/dL, preserve hepatic and
      renal function, stage (TNM AJCC 7th edition): cT1b-3, N0-1, M0, signature of the informed
      consent. Exclusion criterias are: history of another cancer, except skin non melanoma,
      pregnancy or history of hypersensitivity to the study drugs
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2017</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>complete pathological response</measure>
    <time_frame>2 weeks after surgery</time_frame>
    <description>complete pathological response will be evaluate in the surgical specimen after the neoadjuvant treatment</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Esophageal Cancer</condition>
  <condition>Induction Chemotherapy</condition>
  <arm_group>
    <arm_group_label>induction carboplatin paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>carboplatin AUC=6 21 day cycle for 2 cycles paclitaxel 175 mg/m2 21 day cycle for 2 cycles radiotherapy 4500 cGy in 25 fractions carboplatin AUC=2 in a week regimen during radiotherapy paclitaxel 50 mg/m2 in a week regimen during radiotherapy Minimal Invasive Surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin paclitaxel</intervention_name>
    <description>induction carboplatin paclitaxel for 2 cycles</description>
    <arm_group_label>induction carboplatin paclitaxel</arm_group_label>
    <other_name>Taxol, Carbo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven adenocarcinoma or squamous cell carcinoma of the middle and
             lower third of the esophagus (included tumors located in the gastro-esophageal
             junction Siewert I and II)

          -  Age between 18 and 75 years

          -  Performance Status 0 or 1

          -  Stage (TNM AJCC 7th edition): cT1b-3, N0-1, M0

        Exclusion Criteria:

          -  History of another cancer, except skin non melanoma

          -  Pregnancy

          -  History of hypersensitivity to the study drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mariana Siqueira, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>INCA Brazil</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mariana Siqueira, MD</last_name>
    <phone>+552132071024</phone>
    <email>maribruno2003@yahoo.com.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alessandra Marins</last_name>
    <phone>+552132076665</phone>
    <email>amarins@inca.gov.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>INCA- Instituto Nacional de CÃ¢ncer</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>20231-050</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandra Marins</last_name>
      <phone>00552132076666</phone>
    </contact>
    <contact_backup>
      <last_name>Andrea Roza</last_name>
      <email>aroza@inca.gov.br</email>
    </contact_backup>
    <investigator>
      <last_name>Juliana O Souza, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luiz Henrique Araujo, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Siqueira B Mariana, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 31, 2016</study_first_submitted>
  <study_first_submitted_qc>October 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2016</study_first_posted>
  <last_update_submitted>March 19, 2018</last_update_submitted>
  <last_update_submitted_qc>March 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Nacional de Cancer, Brazil</investigator_affiliation>
    <investigator_full_name>Mariana Bruno Siqueira</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

